http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 02:37:04 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/B.Riley+Starts+Spruce+Biosciences%2C+Inc.+%28SPRB%29+at+Buy/26758742.html <p>B.Riley analyst Madison El-Saadi initiates coverage on Spruce Biosciences, Inc. (NASDAQ: SPRB) with a Buy rating and a price target of $160.00.</p><p>The analyst comments: “We are launching coverage on Spruce Biosciences (SPRB) with a Buy rating and a $160 PT. SPRB is developing TA-ERT, an enzyme replacement therapeutic delivered directly into the CNS, that treats MPS IIIB, an ultra-rare and fatal genetic pediatric disease with no approved therapies. In our view, the stock setup is unusually clean, where we see a path to re-rating ahead of its planned BLA submission by YE26 (and potential approval/launch 1H/Mid-27), as shares have retracted http://www.streetinsider.com/New+Coverage/B.Riley+Starts+Spruce+Biosciences%2C+Inc.+%28SPRB%29+at+Buy/26758742.html Mon, 13 Jul 2026 02:37:04 -0400 SPRB http://www.streetinsider.com/Analyst+Comments/B.Riley+Starts+Spruce+Biosciences%2C+Inc.+%28SPRB%29+at+Buy/26758742.html <p>B.Riley analyst Madison El-Saadi initiates coverage on Spruce Biosciences, Inc. (NASDAQ: SPRB) with a Buy rating and a price target of $160.00.</p><p>The analyst comments: “We are launching coverage on Spruce Biosciences (SPRB) with a Buy rating and a $160 PT. SPRB is developing TA-ERT, an enzyme replacement therapeutic delivered directly into the CNS, that treats MPS IIIB, an ultra-rare and fatal genetic pediatric disease with no approved therapies. In our view, the stock setup is unusually clean, where we see a path to re-rating ahead of its planned BLA submission by YE26 (and potential approval/launch 1H/Mid-27), as shares have retracted http://www.streetinsider.com/Analyst+Comments/B.Riley+Starts+Spruce+Biosciences%2C+Inc.+%28SPRB%29+at+Buy/26758742.html Mon, 13 Jul 2026 02:37:04 -0400 SPRB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SPRUCE+BIOSCIENCES%2C+INC.++For%3A+Jun+30++Filed+by%3A+Szwarcberg+Javier+B./26753379.html si-local-file:///var/storage/secattach/20260709/26753379.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SPRUCE+BIOSCIENCES%2C+INC.++For%3A+Jun+30++Filed+by%3A+Szwarcberg+Javier+B./26753379.html Thu, 09 Jul 2026 16:15:00 -0400 O.37894223 SPRB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SPRUCE+BIOSCIENCES%2C+INC.++For%3A+Jun+30++Filed+by%3A+Szwarcberg+Javier+B./26753379.html si-local-file:///var/storage/secattach/20260709/26753379.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SPRUCE+BIOSCIENCES%2C+INC.++For%3A+Jun+30++Filed+by%3A+Szwarcberg+Javier+B./26753379.html Thu, 09 Jul 2026 16:15:00 -0400 O.37894223 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebio.com%2F&amp;esheet=54567244&amp;newsitemid=20260708053762&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc.&amp;index=133&amp;md5=fc5f8b2d2229a3c8cc5d30fc89d600da" shape="rect">Spruce Biosciences, Inc.</a> (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.</p><p>The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.</p><p>Participation in the http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html Wed, 08 Jul 2026 16:01:00 -0400 A.50202486 O.37894223 O.53171475 SPRB SPRUCEBIO http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebio.com%2F&amp;esheet=54567244&amp;newsitemid=20260708053762&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc.&amp;index=133&amp;md5=fc5f8b2d2229a3c8cc5d30fc89d600da" shape="rect">Spruce Biosciences, Inc.</a> (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.</p><p>The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.</p><p>Participation in the http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html Wed, 08 Jul 2026 16:01:00 -0400 A.50202486 O.37894223 O.53171475 SPRB SPRUCEBIO http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebio.com%2F&amp;esheet=54567244&amp;newsitemid=20260708053762&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc.&amp;index=133&amp;md5=fc5f8b2d2229a3c8cc5d30fc89d600da" shape="rect">Spruce Biosciences, Inc.</a> (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.</p><p>The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.</p><p>Participation in the http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html Wed, 08 Jul 2026 16:01:00 -0400 A.50202486 O.37894223 O.53171475 SPRB SPRUCEBIO http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebio.com%2F&amp;esheet=54567244&amp;newsitemid=20260708053762&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc.&amp;index=133&amp;md5=fc5f8b2d2229a3c8cc5d30fc89d600da" shape="rect">Spruce Biosciences, Inc.</a> (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.</p><p>The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.</p><p>Participation in the http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html Wed, 08 Jul 2026 16:01:00 -0400 A.50202486 O.37894223 O.53171475 SPRB SPRUCEBIO http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebio.com%2F&amp;esheet=54567244&amp;newsitemid=20260708053762&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc.&amp;index=133&amp;md5=fc5f8b2d2229a3c8cc5d30fc89d600da" shape="rect">Spruce Biosciences, Inc.</a> (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.</p><p>The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.</p><p>Participation in the http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html Wed, 08 Jul 2026 16:01:00 -0400 A.50202486 O.37894223 O.53171475 SPRB SPRUCEBIO http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebio.com%2F&amp;esheet=54567244&amp;newsitemid=20260708053762&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc.&amp;index=133&amp;md5=fc5f8b2d2229a3c8cc5d30fc89d600da" shape="rect">Spruce Biosciences, Inc.</a> (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.</p><p>The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.</p><p>Participation in the http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html Wed, 08 Jul 2026 16:01:00 -0400 A.50202486 O.37894223 O.53171475 SPRB SPRUCEBIO http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebio.com%2F&amp;esheet=54567244&amp;newsitemid=20260708053762&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc.&amp;index=133&amp;md5=fc5f8b2d2229a3c8cc5d30fc89d600da" shape="rect">Spruce Biosciences, Inc.</a> (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.</p><p>The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.</p><p>Participation in the http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html Wed, 08 Jul 2026 16:01:00 -0400 A.50202486 O.37894223 O.53171475 SPRB SPRUCEBIO http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebio.com%2F&amp;esheet=54567244&amp;newsitemid=20260708053762&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc.&amp;index=133&amp;md5=fc5f8b2d2229a3c8cc5d30fc89d600da" shape="rect">Spruce Biosciences, Inc.</a> (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.</p><p>The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.</p><p>Participation in the http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html Wed, 08 Jul 2026 16:01:00 -0400 A.50202486 O.37894223 O.53171475 SPRB SPRUCEBIO http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebio.com%2F&amp;esheet=54567244&amp;newsitemid=20260708053762&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc.&amp;index=133&amp;md5=fc5f8b2d2229a3c8cc5d30fc89d600da" shape="rect">Spruce Biosciences, Inc.</a> (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.</p><p>The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.</p><p>Participation in the http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html Wed, 08 Jul 2026 16:01:00 -0400 A.50202486 O.37894223 O.53171475 SPRB SPRUCEBIO http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebio.com%2F&amp;esheet=54567244&amp;newsitemid=20260708053762&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc.&amp;index=133&amp;md5=fc5f8b2d2229a3c8cc5d30fc89d600da" shape="rect">Spruce Biosciences, Inc.</a> (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.</p><p>The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.</p><p>Participation in the http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+to+Participate+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26747461.html Wed, 08 Jul 2026 16:01:00 -0400 A.50202486 O.37894223 O.53171475 SPRB SPRUCEBIO http://www.streetinsider.com/Index+Changes/Spruce+Biosciences+added+to+Russell+3000+Index/26702385.html <p>Spruce Biosciences, Inc. (Nasdaq: SPRB) has been added to the Russell 3000® Index, effective with the opening of U.S. equity markets, as part of the 2026 Russell U.S. Indexes Reconstitution.</p> <p>The Russell 3000® Index tracks the largest U.S.-listed companies by total market capitalization and is maintained by FTSE Russell. Inclusion in the Russell 3000® also results in automatic inclusion in the small-cap Russell 2000® Index. Both indexes are used by investment managers and institutional investors for index-based and active investment strategies.</p> <p>Samir Gharib, President and Chief Financial Officer of Spruce Biosciences, said the addition "reflects the progress we have made as a http://www.streetinsider.com/Index+Changes/Spruce+Biosciences+added+to+Russell+3000+Index/26702385.html Mon, 29 Jun 2026 08:01:17 -0400 O.37894223 SPRB http://www.streetinsider.com/Index+Changes/Spruce+Biosciences+added+to+Russell+3000+Index/26702385.html <p>Spruce Biosciences, Inc. (Nasdaq: SPRB) has been added to the Russell 3000® Index, effective with the opening of U.S. equity markets, as part of the 2026 Russell U.S. Indexes Reconstitution.</p> <p>The Russell 3000® Index tracks the largest U.S.-listed companies by total market capitalization and is maintained by FTSE Russell. Inclusion in the Russell 3000® also results in automatic inclusion in the small-cap Russell 2000® Index. Both indexes are used by investment managers and institutional investors for index-based and active investment strategies.</p> <p>Samir Gharib, President and Chief Financial Officer of Spruce Biosciences, said the addition "reflects the progress we have made as a http://www.streetinsider.com/Index+Changes/Spruce+Biosciences+added+to+Russell+3000+Index/26702385.html Mon, 29 Jun 2026 08:01:17 -0400 O.37894223 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Joins+the+Russell+3000%C2%AE+Index/26702264.html <p class="bwalignc"> <i>Inclusion Reflects Spruce’s Momentum as the Company Advances Toward a Planned Biologics License Application (BLA) Submission and Potential Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB)</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connection with the 2026 Russell U.S. Indexes Reconstitution. </p><p> The Russell http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Joins+the+Russell+3000%C2%AE+Index/26702264.html Mon, 29 Jun 2026 08:00:00 -0400 O.37894223 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Joins+the+Russell+3000%C2%AE+Index/26702264.html <p class="bwalignc"> <i>Inclusion Reflects Spruce’s Momentum as the Company Advances Toward a Planned Biologics License Application (BLA) Submission and Potential Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB)</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connection with the 2026 Russell U.S. Indexes Reconstitution. </p><p> The Russell http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Joins+the+Russell+3000%C2%AE+Index/26702264.html Mon, 29 Jun 2026 08:00:00 -0400 O.37894223 SPRB http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+Joins+the+Russell+3000%C2%AE+Index/26702264.html <p class="bwalignc"> <i>Inclusion Reflects Spruce’s Momentum as the Company Advances Toward a Planned Biologics License Application (BLA) Submission and Potential Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB)</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connection with the 2026 Russell U.S. Indexes Reconstitution. </p><p> The Russell http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+Joins+the+Russell+3000%C2%AE+Index/26702264.html Mon, 29 Jun 2026 08:00:00 -0400 O.37894223 SPRB http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+Joins+the+Russell+3000%C2%AE+Index/26702264.html <p class="bwalignc"> <i>Inclusion Reflects Spruce’s Momentum as the Company Advances Toward a Planned Biologics License Application (BLA) Submission and Potential Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB)</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connection with the 2026 Russell U.S. Indexes Reconstitution. </p><p> The Russell http://www.streetinsider.com/Business+Wire/Spruce+Biosciences+Joins+the+Russell+3000%C2%AE+Index/26702264.html Mon, 29 Jun 2026 08:00:00 -0400 O.37894223 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+medical+affairs+VP+ahead+of+drug+review/26670084.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President of Medical Affairs, according to a company press release.</p> <p>Dr. Jurecka brings more than 20 years of clinical and biopharmaceutical experience in rare genetic diseases, including lysosomal storage disorders and enzyme replacement therapies. Most recently, she served as Chief Medical Officer at a seed-stage gene therapy company focused on CNS-directed therapies for lysosomal gene defects. Prior roles include Vice President of Clinical Development at CoA Therapeutics, a BridgeBio company, and Senior Medical Director of Global Clinical Development at Ultragenyx Pharmaceutical. She has also held medical affairs roles http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+medical+affairs+VP+ahead+of+drug+review/26670084.html Mon, 22 Jun 2026 08:00:17 -0400 A.06307404 A.20789085 A.50216925 O.01696526 O.02710883 O.37894223 O.45962571 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+medical+affairs+VP+ahead+of+drug+review/26670084.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President of Medical Affairs, according to a company press release.</p> <p>Dr. Jurecka brings more than 20 years of clinical and biopharmaceutical experience in rare genetic diseases, including lysosomal storage disorders and enzyme replacement therapies. Most recently, she served as Chief Medical Officer at a seed-stage gene therapy company focused on CNS-directed therapies for lysosomal gene defects. Prior roles include Vice President of Clinical Development at CoA Therapeutics, a BridgeBio company, and Senior Medical Director of Global Clinical Development at Ultragenyx Pharmaceutical. She has also held medical affairs roles http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+medical+affairs+VP+ahead+of+drug+review/26670084.html Mon, 22 Jun 2026 08:00:17 -0400 A.06307404 A.20789085 A.50216925 O.01696526 O.02710883 O.37894223 O.45962571 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+medical+affairs+VP+ahead+of+drug+review/26670084.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President of Medical Affairs, according to a company press release.</p> <p>Dr. Jurecka brings more than 20 years of clinical and biopharmaceutical experience in rare genetic diseases, including lysosomal storage disorders and enzyme replacement therapies. Most recently, she served as Chief Medical Officer at a seed-stage gene therapy company focused on CNS-directed therapies for lysosomal gene defects. Prior roles include Vice President of Clinical Development at CoA Therapeutics, a BridgeBio company, and Senior Medical Director of Global Clinical Development at Ultragenyx Pharmaceutical. She has also held medical affairs roles http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+medical+affairs+VP+ahead+of+drug+review/26670084.html Mon, 22 Jun 2026 08:00:17 -0400 A.06307404 A.20789085 A.50216925 O.01696526 O.02710883 O.37894223 O.45962571 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+medical+affairs+VP+ahead+of+drug+review/26670084.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President of Medical Affairs, according to a company press release.</p> <p>Dr. Jurecka brings more than 20 years of clinical and biopharmaceutical experience in rare genetic diseases, including lysosomal storage disorders and enzyme replacement therapies. Most recently, she served as Chief Medical Officer at a seed-stage gene therapy company focused on CNS-directed therapies for lysosomal gene defects. Prior roles include Vice President of Clinical Development at CoA Therapeutics, a BridgeBio company, and Senior Medical Director of Global Clinical Development at Ultragenyx Pharmaceutical. She has also held medical affairs roles http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+medical+affairs+VP+ahead+of+drug+review/26670084.html Mon, 22 Jun 2026 08:00:17 -0400 A.06307404 A.20789085 A.50216925 O.01696526 O.02710883 O.37894223 O.45962571 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+medical+affairs+VP+ahead+of+drug+review/26670084.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President of Medical Affairs, according to a company press release.</p> <p>Dr. Jurecka brings more than 20 years of clinical and biopharmaceutical experience in rare genetic diseases, including lysosomal storage disorders and enzyme replacement therapies. Most recently, she served as Chief Medical Officer at a seed-stage gene therapy company focused on CNS-directed therapies for lysosomal gene defects. Prior roles include Vice President of Clinical Development at CoA Therapeutics, a BridgeBio company, and Senior Medical Director of Global Clinical Development at Ultragenyx Pharmaceutical. She has also held medical affairs roles http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+medical+affairs+VP+ahead+of+drug+review/26670084.html Mon, 22 Jun 2026 08:00:17 -0400 A.06307404 A.20789085 A.50216925 O.01696526 O.02710883 O.37894223 O.45962571 SPRB